scholarly journals Is Invasive Mucinous Breast Carcinoma A Rare Variant With Neuroendocrine Differentiation?

2021 ◽  
Vol 10 (02) ◽  
pp. 168-168
Author(s):  
Ayesha Asghar ◽  
Aresha Masood Shah

We want to bring your attention towards the rare variant of breast cancer hence promoting its early detection and screening. The main advantage of early diagnosis is reduced tumor size without distant dissemination at the initial treatment.

Author(s):  
Yan Shou Zhang ◽  
Chao Yang ◽  
Lei Han ◽  
Lei Liu ◽  
Yun Jiang Liu

Background: Breast cancer resistance protein (BCRP), or ABCG2 (ATP-binding cassette sub-family G member 2), is an ATP-binding cassette (ABC) transporter that mediates energy-dependent transport of substrate drugs out of the cell. Its overexpression may contribute to intrinsic drug resistance in vitro. However, the current literature has not yet clarified the clinical significance of BCRP/ABCG2 in invasive breast carcinoma. Objectives: The purpose of this study was to validate the expression of BCRP/ABCG2 in invasive breast carcinoma and its role in response to neoadjuvant chemotherapy. Methods: In this study, a pretherapeutic core biopsy was performed in 222 patients. BCRP/ABCG2 expression in carcinoma tissue was measured by immunohistochemistry. BCRP/ABCG2 expression correlations with clinicopathological features, molecular subtypes, and therapy response after neoadjuvant chemotherapy were investigated. Results: The results showed that BCRP/ABCG2 was expressed in different molecular subtypes. The proportions of patients with high BCRP/ABCG2 expression were similar in luminal A and luminal B tumors (Luminal B, 80%; Luminal A, 78%), compared with other molecular subtypes (Triple-negative, 63%; HER-2+, 58%. P=0.05). BCRP/ABCG2 expression and the number of lymphatic metastases (𝑃=0.001) and tumor size (𝑃=0.011) demonstrated a statistically significant correlation. Low BCRP/ABCG2 expression was associated with an increased pathological complete response (pCR) rate of 38%, higher than the 19% in tumors with high BCRP/ABCG2 expression (P=0.002). In multivariable analysis, BCRP/ABCG2 and hormone receptor (HR) expression were identified as independent risk factors of pCR (P=0.003, P=0.013. respectively). Conclusions: BCRP/ABCG2 is highly expressed in hormone receptor-positive breast cancer. High BCRP/ABCG2 expression is associated with lymphatic metastasis, tumor size, and poor pCR. BCRP/ABCG2 may be a novel potential biomarker that can predict clinical progression and therapy response after neoadjuvant chemotherapy.


2017 ◽  
pp. 354-388 ◽  
Author(s):  
Surekha Kamath

In this chapter, how medical thermography can be utilized as early detection technique for breast cancer with fuzzy logic is explained. Breast cancer is the leading cause of death among women. This fact justifies researches to reach early diagnosis, improving patients' life expectancies. Moreover, there are other pathologies, such as cysts and benign neoplasms, that deserve investigation. In the last ten years, the infrared thermography has shown to be a promising technique to early diagnosis of breast pathologies. Works on this subject presented results that justify the thermography as a complementary exam to detect breast diseases. Various algorithms that can be utilized for Breast Cancer diagnosis utilizing medical thermography are listed and also the advantages of medical thermography over other imaging modalities is given.


Aim: The lack of structured breast cancer awareness programs (BCAP) in developing countries coupled by the scarcity of radiation oncology centers limit the available surgical options. The aim of this study is to Probe the use Intraoperative radiotherapy (IORT) treatment as a stem to initiate positive impact on early disease detection and propagate breast conserving surgery (BCS). Materials and Methods: This observational review was undertaken at King Fahd hospital of the university, AL Khobar, Eastern province of Saudi Arabia between 2012- 2016. All patients diagnosed with breast cancer were reviewed. Strict recruitment criteria were adopted for patients to receive IORT. Selected candidates where only those who were eligible and consented to undergo BCS and IORT. Special emphasis was placed on demographic data, tumor size at the initial presentation, post Neo-adjuvant chemotherapy response, post–pathology cavity size and applicator size used. Results: The total number of patients diagnosed with breast cancer were 330 out of which 69 (20%) patient were eligible for IORT. Age ranged from31-75years with the Median age 50 years. Applicator sizes used ranged from 2.0-5.0. Tumor size ranged between 0.6-4.0 centimeters. 1 (1%) was post pathology case with excision performed two weeks prior to presentation. 0-1 in 8(11%), 1.1-2 in 22(31%), 2.1-3 in 24(34%), and 3.1- 4.0 in 15 (21%) patients. 7(10%) patients received Neo-adjuvant chemotherapy with positive response and were included. The applicator sizes available ranged between 1.5-5.0 centimeters. Applicator sizes were size 2.0 in 2 (3%), size 2.5 in 10 (14%), size 3.0 in 18(26%), size 3.5 in 16 (23%), size 4.0 in 10 (14%), size 4.5 in 6 cases (9%) and size 5.0 in 7 cases (10%). Smaller applicator sizes 2.0-3.5 centimeter in diameter were used in 46 (66%) of cases suggesting that smaller lesions are currently been diagnosed. Conclusion: The introduction of Intraoperative radiotherapy (IORT) intended as boost therapy is a break through treatment of early breast cancer. While developing countries remain disadvantaged by the lack of adequate radiotherapy centers to cover its population needs, IORT can offer an alternative solution for a selected subset of women with early breast cancer as an exclusive or boost therapy. Its positive impact on the early detection is well illustrated in this observational study. In addition, its use supported the promotion of BCS in early breast cancer thus, it braced a positive impact on early detection strategies.


2021 ◽  
Vol 26 (1) ◽  
pp. 36-40
Author(s):  
Andrei Moisin ◽  
Ciprian Tănăsescu

Abstract Breast cancer is the most common cancer in women and a major public health problem, affecting 2.1 million women each year globally and causing the highest number of cancer-related deaths among women. In 2018, an estimated 627,000 women died from breast cancer (about 15% of all cancer deaths among women). To improve survival, early detection is essential. There are two strategies for early detection of breast cancer: early diagnosis and screening.(1) In Romania, the latest statistics show a higher incidence of breast cancer compared to the European average of 7929 new cases / year with a mortality of 3101 deaths / year.(2)


SINERGI ◽  
2019 ◽  
Vol 23 (2) ◽  
pp. 115
Author(s):  
Yusnita Rahayu ◽  
Immanuel Waruwu

Breast cancer is the transformation of normal cells in the breast area into a malignant tumor, which is the second largest disease as a cause of death for women. Early detection is one way to avoid significant risks in breast cancer.  X-ray mammography and magnetic resonance imaging (MRI) techniques are used to detect breast cancer. However, those techniques have several limitations. Ultra-wideband (UWB) microwave imaging, approved by The Federal Communications Commission (FCC) in the United States, has promising capabilities in detecting breast cancer. Microwave imaging uses a microstrip antenna that has the advantage of convenience, potentially low cost, and is a non-ionized and safe alternative. In this paper, the ultra-wideband microstrip antenna for breast cancer detection is proposed. The antenna was designed by adding some rectangular slots on a rectangular patch to meet the UWB specifications. The antenna works well at 8.41 GHz to 10.29 GHz with directivity of 6.451 dBi and SAR value of 1.6 W / kg. The antenna was simulated with breast phantom. The tumor sizes of 6 mm and 10 mm are added to evaluate the E/H fields and current density with and without tumor. The highest E-Field value of 928.8 V / m was obtained at 10 GHz with a 10 mm tumor size.  The highest H-Field value of 4.06 V / m was achieved at 10 GHz with a 6 mm tumor size. From the simulation, the E/H-field and current density are higher if there is a tumor in the breast compared to the breast without the tumor.


2020 ◽  
Vol 3 (2) ◽  
pp. 37-40
Author(s):  
Ehsan Arjmandzadeh ◽  
◽  
Fariba Binesh ◽  
◽  

Introduction: Breast cancer is known as the most common type of cancer among women in the world. Several methods have been proposed to predict the behavior of breast carcinoma. Recently calretinin has been found to be a reliable factor in predicting tumor survival rate in breast cancer. The aim of this study was to evaluate the relative frequency of calretinin expression in patients with breast cancer in Yazd,Iran. Material and methods: In this cross-sectional retrospective study, the clinicopathologic features and the outcome of patients with breast cancer from 2017 to 2018 were reviewed at Shahid Sadoughi Hospital, Yazd, Iran. The influence of potential prognostic parameters in the overall survival was investigated by log-rank test and Cox regression analysis. Results: Among 100 cases with breast carcinoma, 14.5% were positive for calretinin. The distribution of the rate of positivity of IHC markers including ER, PR, P53, Ki67 and Her2 was 62.9%, 57.1%, 46.2%, 80.5% and 22.1%, respectively. The most common grade and stage were grade2 and stage3 respectively. There was no significant difference in the status of IHC markers (including ER, PR, Her2 and Ki67) in terms of calretinin. 66.7% of the patients with calretinin positive results were P53 positive. The results of the mean tumor size distribution in the two groups of positive and negative calretinin showed a significant difference (P-value = 0.05). A lower age at the time of diagnosis was found in patients with calretinin positive results (P-value = 0.119). The mean survival rate in calretinin positive group was 6.71 years and 6.62 years in calretinin negative patients which was not statistically significant. Conclusion: The results of this study indicated an association between calretinin expression and other IHC markers (although not statistically significant) in predicting poor prognosis in breast cancer patients. In addition, we found a statistically significant association among calretinin with smaller tumor size and lower age at the time of diagnosis in patients with breast cancer.


2011 ◽  
Vol 17 (4) ◽  
pp. 444-447 ◽  
Author(s):  
Umut Demirci ◽  
Suleyman Buyukberber ◽  
Tansel Cakir ◽  
Aylar Poyraz ◽  
Meltem Baykara ◽  
...  

Mucinous breast carcinoma (MBC) is a rare histological type of breast cancer and rarely associated with advanced disease. We report a case that had MBC with an isolated adrenal metastasis which was removed by laparoscopic adrenelectomy. This case is unique due to the unexpected metastasis of pure mucinous carcinoma developed after 4 years of hormone therapy.


Author(s):  
Nada Alwan ◽  
Mena M. Shawkat

Breast cancer ranks the first among the Iraqi population and the leading cause of cancer related female mortality. In addition to the barriers that impede early detection of that cancer other major challenges include the capacity for effective multimodality treatment. Aim: To review and follow up a sample of Iraqi female patients diagnosed with breast cancer in a main referral center; recording their clinico-pathological characteristics, the offered treatment options and the rate of recurrence. Material and Methods: This retrospective study analyzed the clinical and pathological characteristics of 230 Iraqi female patients histologically diagnosed with breast carcinoma who had reliable valid data related to their demographic, clinical and tumor pathological status. The studied parameters included the age of the patient, marital status, parity, age at first delivery, occupation, history of lactation and hormonal intake, family history of breast and any other cancer, histological type, tumor grade and clinical stage. Hormone receptors (Estrogen and Progesterone) and HER2 over expression contents of the primary tumors were evaluated immunohistochemically. The offered treatment options included surgery, chemotherapy, radiotherapy, hormonal and biological targeted therapy. The rate of recurrence was evaluated after a follow-up period of three years. Results: Only 3.5% of the patients were under the age of 30 years while 39.1% were aged 50 years and over. About 84% were married, 11.3% were nulliparous, 24.9% had their first delivery before the age of 20 years and 56.9% were housewives. History of lactation was reported in 60.4%, whereas history of breast cancer was registered in 17.4%. The most common histological type of breast carcinoma was the infiltrative ductal (86.5%), well differentiated carcinomas were diagnosed in only 5.2%. The rates of positive ER, PR and HER2 tumor contents were 68.3%, 65.7% and 29.6% respectively. Overall 8.3%, 4.3%, 39.6% and 7.8% of the patients were diagnosed at stages I, II, III and IV respectively.  Surgery was the primary treatment modality prescribed to the vast majority (96.1%) of the patients; 88.2% of those underwent modified radical mastectomy and only 3.6% had breast conservative surgery. Whereas 91.7% received chemotherapy, radiotherapy, hormonal and biological therapy were applied on 65.7%, 63.5% and 27.4% respectively. Recurrence of breast carcinoma three years following treatment was displayed among 9.7%; displaying significant direct association with the clinical stages of the disease (p<.05). Conclusions: Breast cancer is still diagnosed at relatively advanced stages at the time of first presentation in Iraq; requesting radical mastectomy. Early detection represents the principal approach to control breast cancer in the near future. Regular long-term follow up through multidisciplinary tumor boards is mandatory to monitor response to therapy and recurrence.


Sign in / Sign up

Export Citation Format

Share Document